Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Feedback inks collaboration deal with Vertex In Healthcare
(Sharecast News) - Clinical infrastructure specialist Feedback announced a collaboration agreement with Vertex In Healthcare, a clinical IT firm with a presence in the UK, the UAE, and South Africa, on Wednesday. The AIM-traded firm said the strategic partnership aimed to combine key technologies and resell each other's products to drive commercial opportunities across multiple markets.
It said the agreement would see Feedback integrate the MedDream viewer into its Bleepa platform, which would allow Bleepa to be marketed directly to radiologists for primary diagnostic reporting, enhancing Feedback's teleradiology offering and expanding its market reach to new territories, particularly the US.
By embedding a viewer with regulatory approval in various international markets, the combined Bleepa-MedDream product would reportedly meet the necessary requirements for direct sales.
While Feedback's primary international focus remained on the growing market opportunity in India, the collaboration opened potential expansion into key markets such as the US and the Middle East.
The collaboration also positioned both Feedback and Vertex to resell each other's products in multiple regions, leveraging each other's established footprints to facilitate rapid and cost-effective market expansion.
Bleepa's value and product differentiation were expected to enhance Vertex's existing solutions, helping grow market share across various customer segments.
Additionally, Vertex would licence the database capabilities of Feedback's legacy Cadran PACS system, now integrated with the MedDream Viewer, to develop a PACS proposition for markets including South Africa and the UK.
"Vertex is a great partner for Feedback - like us it is commercially minded, ambitious and on a clear mission to improve healthcare," said chief executive officer Dr Tom Oakley.
"Our products naturally fit together and create a compelling value proposition to customers, especially those who are increasingly looking for the most streamlined and cost-effective way of procuring the solutions that they need.
"Incorporating the MedDream viewer into Bleepa opens up new opportunities for us, both domestically to radiologists and internationally, allowing us to expand more rapidly if we see opportunities overseas, avoiding some of the difficulties that we had in registering Bleepa as a medical device directly in India."
At 1005 BST, shares in Feedback were up 3.82% at 68p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Doing Business with Fidelity | Diversity, Equity & Inclusion Reports | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing programme
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.